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Abstract 
Aims: Heart failure (HF) is a pro-thrombotic state. Both platelet and vascular responses to 
nitric oxide (NO) donors are impaired in HF patients with reduced ejection fraction (HFrEF) 
compared to healthy volunteers (HV) due to scavenging of NO, and possibly also reduced 
activity of the principal NO sensor, soluble guanylate cyclase (sGC), limiting the therapeutic 
potential of NO donors as anti-aggregatory agents. Previous studies have shown that nitrite 
inhibits platelet activation presumptively after its reduction to NO, but the mechanism(s) 
involved remain poorly characterized. Our aim was to compare the effects of nitrite on 
platelet function in HV vs. HF patients with preserved ejection fraction (HFpEF) and chronic 
atrial fibrillation (HFpEF-AF), vs. patients with chronic AF without HF, and to assess whether 
these effects occur independent of the interaction with other formed elements of blood.  
Methods and Results: Platelet responses to nitrite and the NO donor sodium nitroprusside 
(SNP) were compared in age-matched HV controls (n=12), HFpEF-AF patients (n=29) and 
chronic AF patients (n=8). Anti-aggregatory effects of nitrite in the presence of NO 
scavengers/sGC inhibitor were determined and vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation was assessed using Western blotting. In HV and chronic AF, both 
nitrite and SNP inhibited platelet aggregation in a concentration-dependent manner. 
Inhibition of platelet aggregation by the NO donor SNP was impaired in HFpEF-AF patients 
compared to healthy and chronic AF individuals, but there was no impairment of the anti-
aggregatory effects of nitrite.  Nitrite circumvented platelet NO resistance independently of 
other blood cells by directly activating sGC and phosphorylating  VASP.  
Conclusion: We here show for the first time that HFpEF-AF (but not chronic AF without HF) 
is associated with marked impairment of platelet NO responses due to sGC dysfunction and 
nitrite circumvents the “platelet NO resistance” phenomenon in human HFpEF, at least 
partly, by acting as a direct sGC activator independent of NO.   
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Introduction 
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of 
heart failure cases.1  HFpEF is associated with morbidity and mortality close to that of heart 
failure with reduced ejection fraction (HFrEF) and there are no effective therapies 2, 3. Both 
HFrEF and HFpEF are associated with impaired endothelial function and a number of studies 
in patients with HFrEF have demonstrated that tissue responsiveness to direct NO donors in 
blood vessels and platelets are diminished.4, 5  
Atrial fibrillation (AF) commonly accompanies HFpEF (up to 40%) and its presence is 
associated with substantial embolic risk. Whilst warfarin or non-vitamin K antagonist oral 
anticoagulants (NOACs) are commonly prescribed in this setting the haemorrhagic risk in 
these patients (mainly elderly, often with comorbidities) is high. Trials have shown that 
aspirin is relatively ineffective in reducing embolic risk in patients with chronic AF 6 and 
additional therapies that might reduce embolic risk, particularly in those at high risk of 
bleeding complications from warfarin would be potentially valuable. 
Recent onset AF is itself associated with platelet hyperaggregability, in part related to 
impaired NO signalling.7 It is well-established that NO is an important mediator in the 
regulation of vascular tone and inhibitor of platelet aggregation.8 These effects are 
predominantly mediated by the activation of soluble guanylate cyclase (sGC) and cyclic 
guanosine-3’,5-monophosphate (cGMP), which subsequently activates protein kinase G 
(PKG) and leads to phosphorylation of vasodilator-stimulated phosphoprotein (VASP). 9    
 
Circulating blood platelets exhibit abnormalities in patients with acute coronary syndrome 
(ACS), stable angina and ischemic HFrEF, and potent antiplatelet therapy plays a pivotal role 
in management of patients with ACS.10  The phenomenon of “platelet NO resistance” has 
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been well described in these patient cohorts,11 but the mechanism of this diminished anti-
aggregatory effect of NO in platelets remains poorly defined. However, it has been 
postulated that NO resistance is likely to be associated with NO scavenging by superoxide 
believed to be derived predominantly from circulating neutrophils 12. Other proposed 
mechanisms include, oxidation or loss of the haem moiety and/or oxidation of specific 
cysteine thiols of the sGC, thus resulting in an impairment of NO-induced sGC activity.13, 14 
NO resistance has also been described as an independent predictor of increased mortality 
and morbidity in patients with high risk ACS.15 An alternative route to activate the NO-sGC-
cGMP pathway would therefore be beneficial. 
We have previously demonstrated that short-term intravenous sodium nitrite improves 
cardiac and pulmonary hemodynamics in patients with HFrEF,16 and very recent studies 
have shown that nebulized nitrite improves rest and exercise hemodynamics in HFpEF and 
that sodium nitrite infusion improves exercise capacity in HFpEF.17, 18 Whilst nitrite can be 
reduced to NO under hypoxic/acidic conditions some vasodilation is observed even under 
normoxic conditions, potentially via a NO independent mechanism.19  
We have therefore undertaken a study to evaluate the potential of nitrite to circumvent 
“platelet NO resistance” and to compare responses to nitrite vs. the NO donor SNP in 
platelets from patients with HFpEF with chronic atrial fibrillation (HFpEF-AF) with those from 
healthy volunteers (HV) and patients with chronic AF alone. Our results demonstrate that 
platelet NO resistance exists in HFpEF-AF patients, but is not observed in age-matched 
patients with chronic AF without heart failure. Since this phenomenon was observed in 
washed platelets it must be largely independent of superoxide production by neutrophils 
and intrinsic to the platelet. We also show that platelet aggregation in HFpEF-AF is inhibited 
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by nitrite, and that this effect was not impaired when compared to that seen in HV and 
chronic AF.    
Methods 
Subjects 
We studied 12 healthy volunteers (8 males and 4 women), 29 patients diagnosed with 
HFpEF-AF (21 males and 8 women), 8 age-matched patients with chronic AF without HF or 
known coronary artery disease (4 males and 4 women). The healthy volunteers and patients 
were randomly assigned to the pharmacological experiments, with 8-11 participants per 
treatment group. Sixteen young healthy volunteers (9 males and 7 females) were also 
recruited for Western blotting experiments. Healthy volunteers were non-smokers free of 
any cardiovascular risk factors, not on any regular medications, and in particular had not 
taken anti-platelet drugs in the 10 days prior to the study. All patients met the established 
criteria for the diagnosis of HFpEF-AF.20, 21 This included participants who have permanent 
AF and ejection fraction >55% (established by echocardiography during screening).22, 23  
Chronic AF participants included persistent AF with no evidence of HF or known coronary 
artery disease. All participants gave written consent before participation in the study. The 
investigation conforms to the principles outlined in the Declaration of Helsinki. The studies 
were approved by the University of Birmingham Ethics Review Committee (ERN_10-0625 
and ERN_12-1184R2) and West Midlands Coventry and Warwickshire research ethics 
committee (14/WM/1211 and 12/WM/0344).  
Blood sampling and platelet preparation 
Venous blood was drawn in 9NC coagulation sodium citrate 3.2% vacutainer tube (Greiner 
Bio-One, Austria). A preparation of washed platelets was obtained as previously 
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described.24, 25 Whole blood was centrifuged at 200 x g for 20 min and platelet rich plasma 
(PRP) was collected up to 0.5 cm from the interface with the red blood cell (RBC) pellet in 
order to minimise RBCs contamination. Platelets were isolated from PRP by centrifugation 
at 1000 x g for 10 min following addition of PGI2 (0.1µg/ml; to inhibit platelet activation; 
Sigma Aldrich). The resulting platelet pellet was resuspended in Tyrode’s buffer (134mM 
NaCl, 0.34mM Na2HPO4, 2.9mM KCl, 12mM NaHCO3, 20mM HEPES, 5mM glucose, 1mM 
MgCl2, pH 7.3) and centrifuged at 1000 x g in the presence of 0.1µg/ml PGI2. The 
supernatant was discarded and the platelet pellet was resuspended in Tyrode’s buffer. The 
washed platelet suspensions were allowed to rest for 1 h prior to experimentation to allow 
the effects of PGI2 to decay. The level of contamination of our washed platelet preparation 
with plasma constituents was determined using the Bio-Rad assay for protein 
determination. 
Assessment of RBC and Leukocyte contamination in washed platelet preparations 
Flow cytometry was used to determine RBC and leukocyte contamination in washed platelet 
preparations. Platelets (2x108/ml in Tyrode’s containing 10% heat deactivated human 
serum) and RBC (diluted 1:500 in Tyrode’s buffer) were stained with the RBC surface marker 
PE-conjugated anti CD235a (eBioscience) or isotype IgG control (eBioscience) for 20 min in 
the dark. Cells were washed and acquired with a C6 Accuri flow cytometer. RBC was gated 
using anti-CD235a (eBioscience) and applied to the washed platelet preparation to assess 
RBC contamination. To assess leukocyte contamination in preparations of washed platelets, 
platelets and leukocytes were labelled with anti-CD45 antibody-allophycocyanin (APC; 
Beckman Coulter) or isotype-APC control (Beckman Coulter) for 30 min at 4°C. 0.3ml of 
blood was fixed using 2% formaldehyde for 10 min and after centrifugation at 500 x g for 5 
min, blood was resuspended in 3 ml ACK (Ammonium-Chloride-Potassium) lysis buffer for 
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10 min to remove RBCs. Cells were labelled and washed in PBS at 500 x g for 5 min and 
resuspended in 300μl PBS for analysis on a C6 Accuri flow cytometer. Leukocyte populations 
isolated from whole blood were separated based on forward scatter and CD45 expression. 
Gates based on this distribution were used to assess leukocytes present in preparations of 
washed platelets. 
Oxyhaemoglobin preparation  
Human haemoglobin (Sigma Aldrich) was dissolved in water (20 mg/ml) and reduced by a 
ten-fold molar excess of sodium dithionite (Na2S2O4; Sigma Aldrich). Excess reductant was 
removed by gel filtration over Sephadex G-25 (PD10 desalting column; GE Healthcare) 
according to the manufacturer’s instructions. Oxyhaemoglobin (OxyHb) was eluted with 3.5 
ml of water, and only the middle run was collected. The concentration of OxyHb was 
determined spectrophotometrically, as described.26 Aliquots of the OxyHb stock solution 
were kept at -80C, thawed on the day of experimentation and discarded after use. 
Platelet aggregation  
Washed platelets were suspended at 2x108/ml for light transmission aggregation (LTA) using 
a lumi-dual aggregometer (model 460VS; Chronolog, Labmedics) under continuous stirring 
at 1200 rpm, as previously described.24 Sodium nitrite, sodium nitrate, sodium nitroprusside 
(SNP), 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 2-Phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl 3-oxide (PTIO) (all purchased from Sigma Aldrich), OxyHb, 
BAY 41-2272  or vehicles were incubated for the stated time and concentrations as indicated 
in the figure legends before platelet activation with 3µg/ml collagen (Nycomed).  
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Western blotting 
Washed platelets were suspended at 5x108/ml for Western blot experiments. Platelets were 
incubated as indicated in the figure legends. Incubations were stopped by adding 5x 
reducing sample buffer at the indicated time point. Samples were boiled for 5 min and spun 
prior to SDS-PAGE (10%) and transferred onto a polyvinylidene fluoride (PVDF; GE 
Healthcare) membrane. PVDF membranes were incubated with antibodies against p-Serine 
239 VASP (Cell signalling Technology) and α-tubulin (Sigma Aldrich) overnight at 4˚C. 
Membranes were then incubated with appropriate secondary antibodies (anti-rabbit (GE 
healthcare) and anti-mouse (Dako)) as detailed in figure legend text. Band densitometry was 
performed as previously described. 27 
Statistical analysis  
Results are presented either as representative experiment of n experiments performed or as 
average ± standard error of the mean (SEM). Differences between groups were analysed 
using the, Fisher’s exact test, unpaired t-test, 1-way ANOVA or 2-way ANOVA by Dunnett’s 
or Sidak’s multiple comparisons test as appropriate. Within group differences was assessed 
by Wilcoxon matched-pairs signed rank test. P<0.05 was considered significant. All analyses 
were performed using Prism version 7.0 (GraphPad Inc., Lo Jolla, CA). 
Results 
Healthy volunteers and Heart Failure patients’ characteristics 
Table 1 summarizes the subject characteristics including drug therapies. Patients and 
healthy controls were well matched in terms of age (P=0.40; one-way ANOVA) and gender 
(P=0.53; Fisher’s exact test). Young healthy volunteers (whose blood was used for platelet 
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isolation and Western blotting) were well matched in terms of gender to HFpEF-AF group 
(P=0.33; Fisher’s exact test).  
Washed platelet preparation 
All experiments presented in this study utilized a preparation of washed platelets in order to 
exclude the interference of other blood cell types and to minimise the contribution of 
plasma proteins and other blood cell types to the effects that nitrite may have on platelet 
function. RBCs in particular contain (heme-mediated) nitrite reductase activities, which are 
able to reduce nitrite to NO, potentially augmenting the inhibitory effects of nitrite on 
platelets. Perhaps even more importantly, RBCs also contain high concentrations of 
oxygenated haemoglobin, which is an effective NO scavenger.  Contamination of RBCs was 
evaluated in our platelet preparation by FACS as shown in Figure 1a and b, less than 
0.035±0.02% RBC contamination was present in a preparation of washed platelets. 
Contamination by leukocytes was also excluded using a similar approach. Figure 1c and d 
shows that CD45 positive cells were effectively absent from washed platelet preparations; 
on average fewer than 1 leukocyte per 1000 platelets were found to be present (Figure 1d), 
and plasma proteins concentration was confirmed to be negligible in the 2nd washed 
platelets (-2±0.01 %) when compared to PRP (100±0.55 %) and 1st wash (20±0.01%; Figure 
1e).  
Nitrite circumvents “platelet NO resistance” in patients with HFpEF and chronic AF 
Concentration response to collagen (1, 3 and 10 μg/ml) was conducted to determine the 
concentration used for platelet aggregation experiments (data not shown). A collagen dose 
(3 μg/ml) that achieved a 50% aggregatory response in platelets was selected for the 
present study.24   The effects of nitrite on platelet aggregation in HV, HFpEF-AF, and chronic 
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AF patients alone were studied using 3 μg/ml collagen (Figure 2a). Incubation with nitrite in 
healthy volunteers induced significant concentration-dependent inhibition of platelet 
aggregation in response to collagen (p<0.0001 at 100µM and 1mM; n=10; Figure 2a), 
indicating that nitrite is able to affect platelet function in the absence of other cell types or 
extracellular proteins. A similar trend was also observed with the NO donor, SNP, with 
significant concentration-dependent attenuation of platelet aggregation at 10 and 100 nM 
in response to collagen (p<0.01 at 10nM and p<0.0001 at 100nM; n=8; Figure 2b).   
We next investigated whether nitrite inhibited platelet aggregation following administration 
of 3μg/ml collagen (Figure 2a) in patients from HFpEF-AF. Nitrite significantly attenuated 
platelet aggregation with 1mM nitrite (P<0.0001; n=10), whilst SNP (10 and 100 nM) showed 
no diminution of response to collagen activated platelets (n=8; Figure 2b). To determine 
whether increased concentrations (1 and 10µM) of SNP attenuated platelet aggregation in 
HFpEF-AF group, we observed that SNP caused 45.20±5.45 and 43.11±5.0 % inhibition in 
aggregation, respectively (Supplementary Figure 1).  
To validate whether the SNP responses to collagen were more markedly affected than those 
of nitrite in the HFpEF-AF group, we compared the differences in nitrite and SNP response to 
collagen at the highest doses used to their respective control HFpEF-AF. As shown in Figure 
2c, 10µM SNP (13.15±3.5 % inhibition) demonstrated impaired responses compared to 
1mM nitrite (29.12±5.4 % inhibition; P <0.05).     
To ascertain whether the platelet responses observed with nitrite and SNP in HFpEF-AF 
patients were attributable to the HF, the chronic AF or both we then measured platelet 
aggregation responses in a sub-group of patients with chronic AF alone. Both nitrite and SNP 
induced concentration-dependent attenuation of platelet aggregation in response to 
collagen (Figure 2a; p<0.0001 nitrite (1mM); and Figure 2b P<0.01 (10nM) and p<0.0001 
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SNP, respectively).  Representative traces for HV, HFpEF-AF and cAF alone are shown in 
Figure 3. 
To assess the mechanism by which high concentrations of nitrite circumvent platelet NO 
resistance, we first assessed whether nitrite is converted to NO under these experimental 
conditions by using two different NO scavengers (PTIO and OxyHb). In both healthy 
volunteers (Figure 4a (n=8) and 4b (n=11) and patients with HFpEF (Figure 4d (n=8) and 4e 
(n=9)), neither PTIO nor OxyHb were able to revert the inhibition caused by a high 
concentration of nitrite on platelet aggregation. In order to test the efficacy of PTIO and 
OxyHb we also assessed aggregation in healthy volunteers in the presence of the NO donor 
SNP. As depicted in Figure 4 (a-b), inhibition to SNP was reversed by both NO scavengers.  
To delineate the possible role for sGC, we used the sGC inhibitor, ODQ in combination with 
an inhibitory concentration of nitrite and studied collagen aggregation (Figure 4c and 4f). 
ODQ reverted SNP-dependent inhibition in HV and nitrite-dependent inhibition in both 
healthy subjects (Figure 4c; n=8) and HFpEF-AF (Figure 4f; n=9), indicating that nitrite indeed 
acts through sGC. Representative traces for Figure 4 are shown in Supplementary Figure 2. 
Interestingly, the sGC dependent effect of nitrite on HV platelets exhibited synergistic 
activity with the NO-independent sGC activator, Bay 41-2272 (p<0.001 30nM Bay 41-2272 
plus 10 and 100 µM nitrite, respectively; n=11, supplementary Figure 3b). A similar trend 
was also observed with SNP as a positive control (30nM Bay 41-2272 plus 10nM SNP 
(p<0.01) and 100 nM SNP (p<0.001), respectively; supplementary Figure 3c).   
Nitrite phosphorylates serine-239 vasodilator-stimulated phosphoprotein 
To confirm that the effects of nitrite on platelet aggregation occur via the activation of the 
sGC-cGMP pathway, we next studied the status of phosphorylation of the cyclic nucleotide 
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downstream substrate VASP. In order to understand the normal physiology vs disease 
physiology of nitrite mechanism in washed platelets, VASP serine-239 phosphorylation 
(mainly dependent on cGMP elevation) was assessed from young healthy volunteers vs 
HFpEF-AF (Figures 5a-b). VASP serine-239 phosphorylation was increased with nitrite in a 
concentration-dependent manner as compared to the NO donor SNP. All concentrations of 
nitrite reached a peak after 5-10 min of incubation and then decreased to low levels at 45 
min. VASP serine-239 phosphorylation with 100µM and 1mM nitrite were similar to that 
triggered by treatment with 10 and 100nM SNP, respectively (n=5).  
To determine whether the underlying mechanism of nitrite was NO dependent or 
independent, we measured serine-239 phosphorylation of VASP following the use of PTIO 
and OxyHb. We found that in the presence of NO scavengers, VASP serine-239 was 
phosphorylated by nitrite in both young healthy volunteers (Figure 6a and b; n=9) and 
HFpEF-AF patients (Figure 6c and d; n=10). We next investigated whether nitrite activated 
sGC to phosphorylate serine-239 VASP. VASP phosphorylation on Serine-239 triggered by 
nitrite was completely blocked by ODQ in both healthy volunteers and patients with HFpEF-
AF, thus corroborating our findings from platelet aggregation experiments (Figure 4a-f).   
Nitrate does not affect platelet aggregation and VASP phosphorylation  
The effects of oral inorganic nitrate are usually considered to be dependent on 
enterosalivary circulation of nitrate with reduction of salivary nitrate to nitrite by oral 
bacteria, but a direct effect of nitrate cannot be excluded. We therefore assessed the effect 
of a high concentration of sodium nitrate (1mM) added in vitro on collagen-induced 
aggregation in young healthy volunteers (Figure 7a). In the absence of a functional nitrate 
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reductase, the addition of nitrate to platelets in vitro had no effect on aggregation (P>0.05; 
n=5) or phosphorylation of VASP serine-239 (Figure 7b).   
Discussion  
In the present study, we show several important new findings: first, platelet NO resistance 
exist in patients with HFpEF with associated chronic atrial fibrillation compared to age-
matched healthy volunteers. Second, while NO resistance has been observed in recent 
onset AF7 we did not observe it in age-matched patients with chronic AF in the absence of 
heart failure. Taken together, these data suggest that the platelet NO resistance is 
attributable predominantly to the HFpEF rather than the associated chronic AF. Third, this 
NO resistance was observed in washed platelets indicating that platelet NO resistance is 
largely intrinsic to the platelet. Fourth, nitrite inhibits platelet aggregation in HFpEF-AF 
patients by circumventing the platelet NO resistance phenomenon by directly activating sGC 
and phosphorylating VASP serine 239 independent of NO and the interaction with other 
formed elements of blood and their constiuents such as mitochondria (neutrophils) or 
haemoglobin (red blood cells).  
Approximately half of all cases of HF have HFpEF and the syndrome is frequently associated 
with atrial fibrillation. 28  The pathophysiology of HFpEF is associated with abnormalities in 
left ventricular diastolic reserve, impaired systolic reserve, peripheral and pulmonary 
vasodilatation, endothelial dysfunction and right ventricular dysfunction related to the 
presence of pulmonary hypertension. 29  
Recent studies have postulated that impairment of the NO-cGMP pathway may also play a 
contributing factor in the hemodynamic abnormalities observed in HFpEF. 30, 31 However, to 
our knowledge the role of the NO-cGMP pathway on platelet function in patients with 
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HFpEF with chronic atrial fibrillation has not been previously evaluated.  It is well- 
documented that impaired platelet responsiveness to NO donors (organic nitrates and SNP) 
occurs in a number of cardiovascular disease states, such as ischemic heart disease, HFrEF, 
and in new onset of atrial fibrillation. 4, 7, 15 Herein, we sought to determine whether NO 
donors also have a similar impact on the function of platelets isolated from HFpEF patients 
with chronic atrial fibrillation. We demonstrate for the first time that “platelet NO 
resistance” exists in HFpEF associated with chronic atrial fibrillation. We used SNP, a well-
established NO donor, to evaluate the impact of activation of the sGC-cGMP pathway on 
platelet aggregation. 4, 32 Platelet responsiveness to the NO donor SNP from HFpEF-AF were 
diminished following platelet activation with collagen when compared to platelets from 
healthy volunteers.  
It is now appreciated that under certain conditions nitrite can serve as an alternative source 
of NO in the vasculature and other tissues. 19, 33 Recent studies have  shown that the nitrate-
nitrite-NO pathway inhibits platelet activation. 34-36 It has also been suggested that platelets 
possess the ability to generate transient NO signals from nitrite in the absence of other 
blood cell types through an unidentified mechanism. 34 
Although the role of endothelial-derived NO on platelet function is well characterised, 37 the 
mechanism(s) by which nitrite inhibit platelet aggregation remain poorly defined. Platelets 
are exposed not only to endothelial NO but also to circulatory nitrite, and this could 
represent a source of NO and an alternative mechanism of control of platelet activation.  
Basal circulating nitrite levels in human plasma range are typically in the submicromolar 
range38, 39 and this can rise to levels >8µM upon therapeutic nitrite application.17, 18 
However, local concentrations in the microcirculation of mucosal membranes are likely 
considerably higher. In the oral cavity, nitrite concentrations reach micromolar 
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concentrations even under normal physiological conditions, and salivary nitrite 
concentrations may reach 1-2 mM after dietary nitrate. 40, 41 If nitrite were to be used as a 
therapeutic agent to treat HFpEF-AF, concentrations of this mediator would exceed those 
physiological levels by far, with possible effects on platelet function. A similar scenario is 
likely to occur at the alveolar-arterial interface of the pulmonary circulation following 
therapeutic application of nebulized nitrite.  
The present study was motivated by the paucity of information on the signalling cascade 
leading to platelet inhibition by nitrite. Whilst it is generally assumed that nitrite requires 
prior reduction to NO to become bioactive, this process is remarkably inefficient under 
normoxic conditions, and not all of its actions appear to be accompanied by the generation 
of free NO. 19, 42 To determine whether nitrite inhibits platelet aggregation independently of 
haemoglobin, we used a well-established washed platelet aggregation technique.43 Washed 
platelets are routinely used to assess pharmacological agents on platelet function and 
mechanism in the absence of plasma proteins, enzymes and blood cells. Our results 
demonstrate that platelets from HV are inhibited by nitrite through the activation of sGC (as 
assessed via the sGC inhibitor ODQ; Figure 4). We next sought to determine whether these 
effects were NO dependent. Both NO scavengers (PTIO and OxyHb) effectively reverted the 
effects of an inhibitory concentration of SNP on platelet aggregation (Figure 4). By contrast 
neither PTIO nor OxyHb were able to revert the inhibition caused by a high concentration of 
nitrite on platelet aggregation from HV. VASP phosphorylation on Ser239 triggered by nitrite 
was completely blocked by ODQ (Figure 6), but inhibition was only partial with PTIO and 
OxyHb (Figure 6). Collectively, these data indicate that the antiaggregatory effects of nitrite 
are only partly mediated by NO. This is consistent with additional findings showing that the 
effects of nitrite are potentiated by the NO-independent sGC activator Bay 41-2272 
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(Supplementary Figure 3). It is conceivable, therefore, that part of the effects of nitrite are 
mediated by a modulation of (one or more) cysteine thiols of sGC; whether this is via S-
nitrosation or S-thiolation (e.g sulfhydration or formation of a mixed disulphide with 
another low-molecular weight thiol such as cysteine or glutathione, and therefore oxidation 
of a regulatory thiol in sGC)13, 14 or another mechanism (such as the loss of heme, which 
renders sGC unresponsive to NO) was beyond the remit of the present study and warrants 
further investigation.  
Previous studies have suggested that nitrite therapy may not be subject to the development 
of tolerance.44 Furthermore, we and others have very recently explored nitrite as a potential 
treatment of heart failure. We have shown that short-term intravenous sodium nitrite 
improves cardiac and pulmonary in patients with HFrEF,16 and very recent studies by 
Borlaug and colleagues have demonstrated that acute nitrite infusion 18 or nebulized nitrite 
improves rest and exercise hemodynamics and exercise capacity in HFpEF 17. To assess 
whether nitrite inhibits platelet aggregation in this group of patients, we next assessed the 
effects of nitrite on platelet function.  In the presence of “NO resistance”, nitrite inhibits 
platelet aggregation. To assess the potential mechanism by which nitrite mediates these 
promising effects, platelet responses to nitrite was assessed in the presence of sGC inhibitor 
or NO scavengers. We show that the platelet responsiveness to nitrite was significantly 
attenuated in the presence of ODQ (Figure 4), but both NO scavengers were unable to 
revert the inhibition caused by a high concentration of nitrite on platelet aggregation and 
VASP serine 239 phosphorylation (Figure 6).  Herein, we show for the first time that nitrite 
circumvents the platelet NO resistance in patients with HFpEF-AF. A similar result was also 
observed with our Western blot data. However, heme-containing components (cytochrome 
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C) of the mitochondrial respiratory chain of platelets may convert nitrite to NO45 inside of 
the platelet, thus avoiding the scavenging by OxyHb or PTIO.  
A number of studies have associated AF with inflammation, endothelial dysfunction and in 
particular in the new onset AF with impaired platelet NO response.7 Procter et al (2015) 
have previously reported that acute onset AF is associated with platelet NO resistance, 
whilst responses to NO donor (SNP) were not impaired in chronic AF patients. To validate 
whether the platelet NO resistance observed in the HFpEF-AF with SNP, was HFpEF 
dependent and not AF, we also assessed the effects of nitrite and SNP in a sub-group of 
patients with chronic AF alone. There was approximately 2-fold variability between HFpEF-
AF vs chronic AF subgroups with SNP, therefore further supporting platelet NO resistance in 
patients with HFpEF-AF. In addition, nitrite also inhibited platelet aggregation in a dose-
dependent manner in the chronic-AF sub group.  
ACE inhibitors have previously been shown to reduce platelet NO resistance.46 Whilst 10 of 
the 29 patients with HFpEF-AF were taking ACE inhibitors, NO resistance was observed 
whether or not the patients were taking ACE inhibitors. Two of the 8 patients with chronic 
AF alone were taking ACE inhibitors, but in contrast platelet NO responsiveness was not 
observed in either of these two patients or the six who were not taking ACE inhibitors. 
Previous studies have demonstrated that cGMP plays a key role in determining the 
functional and hemodynamic abnormalities developing in HFpEF. 30 In the present study, we 
show that cAF in the absence of HF respond to NO donors and there is a clear difference in 
response of “NO resistance” in patients with HFpEF-AF. This suggests that phenotyping of 
patients according to their “NO-stimulatable” component in platelet reactivity might allow 
to stratify them to different pharmacological treatment (e.g. personalised medicine).   
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Herein, we have compared the effects of nitrite on platelet function in patients with chronic 
AF with and without HFpEF to conclude about HFpEF.  This study could have benefited in 
having an additional sub-group of HFpEF patients with sinus rhythm to further validate the 
study. However, as local practice, the majority of HFpEF in sinus rhythm were taking aspirin 
and therefore we were unable to recruit for this study. Thus, this remains a major limitation 
to the current investigation and further studies are warranted to clarify the role of nitrite on 
platelet function in this particular patient cohort.   
A major limitation of the current findings is that the concentrations of nitrite used in this 
study are clearly pharmacological, therefore the observations do not imply a physiological 
role for normal plasma nitrite concentrations in the modulation of platelet function. 
Nevertheless, they may have implications for therapy. Recent studies have suggested a 
potentially beneficial effect of the nitrate/nitrite pathway on hemodynamics and exercise 
capacity in HFpEF, the present study raises the potential that such therapy may also reduce 
the burden of thromboembolic disease seen HFpEF patients with chronic atrial fibrillation.  
Furthermore, we observed a decreased platelet aggregation response to collagen in the 
control chronic AF when compared to age-matched control groups from healthy volunteers 
and HFpEF-AF patients. To our knowledge the effects of collagen on washed platelet 
aggregation from chronic AF has not been investigated before, but we have previously 
assessed platelet aggregation (platelet rich plasma) in patients with AF on no therapy to 
have 24% inhibition of aggregation in response to 2mg/ml collagen.47 We have reported the 
complexity of the events of platelet activation in AF and therefore further studies are 
warranted to clarify the role of nitrite and NO donors in the disease states investigated 
herein.   
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In conclusion, we show for the first time that HFpEF is associated with marked impairment 
of platelet NO responses and that nitrite circumvents the “platelet NO resistance” 
phenomenon in human HFpEF, at least in part by acting as a sGC activator. Our findings are 
consistent with the notion that thiol oxidation at the level of the NO-receptor, sGC may play 
a major role in the phenomenon of “NO resistance”; this would seem to warrant further 
investigation. Our findings may also have relevance to the condition of pulmonary 
hypertension (PH) since coagulation has been implicated in the pathogenesis of this disease. 
Although the use of anticoagulation as part of the treatment in PH remains controversial, 
recent PH experimental studies suggest that nitrite may provide some benefit in this 
setting.48 Thus, our data implicate an alternative strategy to potentiate efficacy of direct sGC 
activation, and perhaps may reduce the risk of thrombotic complications in PH. 
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Table 1. Subject characteristics of healthy volunteers, HFpEF with chronic AF and chornic 
AF.  
Values are mean ± SD. NYHA, New York Heart Association classification; HFpEF = Heart 
Failure with preserved ejection fraction; ACE-inhibitors, angiotensin-converting enzyme 
inhibitors.    
Figure legends 
Figure 1. Staining of RBCs and leukocytes in a preparation of washed platelets. RBCs and 
platelets were stained with 0.2 µg anti CD235a PE-conjugated antibody or with IgG isotype 
control. Representative overlay plots are shown (RBCs on the left and platelets on the right) 
(a). A gate was drawn to include 97-99% of RBCs and applied to the washed platelet sample; 
cells in the gate were counted as RBCs contaminating the preparation (b, n=8). RBCs were 
lysed in whole blood and the remaining cells or a suspension of washed platelets were 
stained with APC-conjugated anti CD45 or with IgG isotype control. Representative overlay 
plots are shown (blood on the left and platelets on the right) (c). A gate was drawn around 
the leukocyte population (d, left panel) and applied to the washed platelet sample stained 
with CD45 or isotype control (d, centre and right panel, respectively) (n=3). (e) Assessment 
of plasma protein contamination was determined in washed platelets (1st and 2nd wash) and 
compared to PRP (n=3).  
Figure 2. Platelet aggregation is inhibited by NaNO2. 2x108/ml washed platelets from 
healthy volunteers, HFpEF-AF and chronic AF alone were incubated with increasing 
concentrations of NaNO2 or SNP for 5 min, activated with 3µg/ml collagen (a-b) and studied 
by light transmission aggregometry (LTA). Statistical differences were determined by 
repeated measures two-way ANOVA with Dunnett’s test for multiple comparisons with the 
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control dose values (** p<0.01, **** p<0.0001). n= 8-10. (c) Platelet responses to nitrite and 
SNP in the HFpEF-AF group. The difference between nitrite (1mM) and SNP (10µM) 
responses to collagen with their respective control HFpEF were analysed. *p<0.05 unpaired 
t test with Welch’s correction. n=8-10.   
Figure 3. Representative platelet aggregation traces for experiments performed from Figure 
2 are shown. Platelet responses to nitrite and SNP from healthy volunteers (a-b, HV), heart 
failure with preserved ejection fraction with chronic atrial fibrillation (c-d, HFpEF-AF) and 
chronic atrial fibrillation (e-f, chronic AF).   
Figure 4. NaNO2 effects on aggregation depend on sGC. 2x108/ml washed platelets from 
healthy volunteers (n= 8-11) were incubated with NO scavengers (a) 100 µM PTIO or (b) 
10µM OxyHb immediately before addition of 1mM NaNO2 or 100nM SNP, or (c) sGC 
inhibitor 10µM ODQ 15 min.  2x108/ml washed platelets from HFpEF patients (n=8-9) were 
incubated with (d) PTIO, or (e) OxyHB or (f) ODQ. Aggregation was triggered by 3µg/ml 
collagen. Representative traces for all the performed experiments are shown in 
Supplementary Figure 2. Repeated measures one-way ANOVA with Dunnett’s test for 
multiple comparisons was performed to compare SNP and nitrite to control.  Differences 
between control scavengers/inhibitors to nitrite was evaluated by Wilcoxon matched-pairs 
signed rank test (* p<0.05, ** p<0.01, *** p<0.001).  
Figure 5. NaNO2 triggers phosphorylation of VASP. 5x108/ml washed platelets from healthy 
young volunteers were incubated with increasing concentrations of NaNO2 or SNP and lysed 
by addition of SDS containing 5x sample buffer at the indicated time point. Aliquots of the 
lysates were used for SDS-PAGE (10%). Blots were probed with anti p-VASP Serine 239 
(1:1000) or α-tubulin (1:5000) and the appropriate secondary antibodies (anti-rabbit or anti-
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mouse 1:10000). Representative blots (a) and densitometrical analysis of all the 
experiments performed (b, n=4-5) are shown.  
Figure 6. NaNO2 upregulates VASP serine-239 phosphorylation NO-independently. 
5x108/ml washed platelets from healthy volunteers (a and b; n=8-9) or HFpEF patients (c 
and d; n=10) were incubated with ODQ, PTIO or OxyHb before addition of NaNO2 for 10 min 
and lysed by addition of 5x sample buffer. Aliquots of the lysates were used for SDS-PAGE 
(10%) and western blot as in Figure 5. Representative blots (a and c) and densitometrical 
analysis of all the experiments performed (b and d) are shown. Statistical differences were 
determined by one-way ANOVA and Dunnet’s post-test. Differences within groups (control 
NO scavengers/sGC inhibitors vs nitrite) were evaluated by Wilcoxon matched-pairs signed 
rank test (*p<0.05; ** p<0.01; *** p<0.001). 
Figure 7. NaNO3 has no inhibitory effects in washed platelets 
5x108/ml washed platelets from healthy volunteers were incubated with increasing 
concentrations of NaNO3 (a, n=5) for 5 min, activated with 3µg/ml collagen.  5x108/ml 
washed platelets from healthy subjects were incubated with 1mM NaNO3, lysed after 10 
min and used for SDS-PAGE and western blot as above. A representative blot is shown (b, 
n=4). 
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Parameter Healthy  
Volunteers  
(n=12) 
HFpEF with Chronic 
AF 
(n=29) 
Chronic AF  
 
(n=8) 
Sex (M/F) 8/4 21/8 4/4 
Age, y (Mean ± SD) 71.3±5.9 74.3±6.2 73.9±7.9 
NYHA-Class I/II/III/ - 23/11/2 - 
Diabetes Mellitus - 2 2 
ACE-inhibitors - 10 2 
Angiotensin II receptor 
blocker 
- 2 2 
Diuretics - 2 4 
β-adrenoceptor 
antagonists  
- 8 6 
α-adrenoceptor 
antagonist 
- 2 - 
Calcium channel blocker  - 9 1 
Statins - 10 2 
Cardiac glycoside - - - 
Digoxin - 4 2 
Anti-arrhythmic  - - 1 
Anti-diabetic - 2 2 
Anti-coagulant  - 26 8 
    
 
Table(s)
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Figure 1. The effect of increasing concentration of SNP on platelet aggregation. 2x108/ml 
washed platelets from HFpEF with chronic were incubated with increasing concentrations of 
SNP for 5 min, activated with 3µg/ml collagen and studied by light transmission aggregometry 
(LTA). Statistical differences were determined by repeated measures two-way one-way 
ANOVA with Dunnett’s test for multiple comparisons (*p<0.05) n= 8  
Figure 2. Representative platelet aggregation traces for experiments performed from Figure 
4 are shown. Platelet responses to nitrite and SNP from healthy volunteers incubated with (a) 
PTIO, (b) OxyHb, and (c) ODQ. Platelet responses to nitrite in heart failure patients with 
chronic atrial fibrillation incubated with (d) PTIO, (e) OxyHb, and (f) ODQ.  
Figure 3. Figure 2. NaNO2 effects on aggregation depend on sGC. 2x108/ml washed platelets 
from age-matched healthy volunteers (n= 3) were incubated with (a) sGC activator Bay 41-
2272 (10-100nM) for 3 min before the addition of 3µg/ml collagen. Platelet aggregation was 
monitored for 5 min. Repeated measures one-way ANOVA with Dunnett’s test for multiple 
comparisons was performed to compare Bay 41-2272 to control (*p<0.05; **p<0.01; 
***p<0.001). In some experiments, 2x108/ml washed platelets were incubated with 
increasing concentrations of (b) NaNO2 or (c) SNP for 5 min before the addition of collagen 
3µg/ml collagen. Bay 41-2272 (30nM) was added 1 min before the addition of collagen (n=11). 
Differences between Bay 41-2272 to nitrite (***p<0.0003) and SNP (**p<0.001; 
***p<0.0003) was evaluated by repeated measures two-way ANOVA followed by Sidak’s 
multiple comparisons test.  
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